Clinical Trials Logo

Depression clinical trials

View clinical trials related to Depression.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05698381 Recruiting - Depression Clinical Trials

Daily Vinegar Ingestion and Metabolic Health

Start date: February 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if vinegar ingestion promotes beneficial changes to metabolic health parameters in healthy, overweight adults.

NCT ID: NCT05697172 Recruiting - Clinical trials for Major Depressive Disorder

Low Intensity Ultrasound Neuromodulation of Repetitive Negative Thinking In Depression

Start date: December 15, 2022
Phase: N/A
Study type: Interventional

The investigators propose to use low-intensity transcranial focused ultrasound (LIFU), a novel neuromodulation method, to probe the causal involvement of individually defined components of an anteromedial brain circuit in the processing of self-referential thoughts, and the production of repetitive negative thinking (RNT), a prominent transdiagnostic manifestation with adverse clinical consequences. The investigators hypothesize that real vs. sham low-intensity sonication of individually-defined anteromedial structures connecting medial orbitofrontal and anterior cingulate cortices with ventral striatum and anterior thalamus will show reduced initiation or maintenance of RNT as measured by (1) Brief State Rumination Inventory (BSRI) scores and distress associated to repetitive negative thoughts, and (2) improvement of the affective valence associated to self-referential adjectives, and that these changes will be associated with decreased connectivity between structures mentioned above. The present early feasibility study is an initial step that aims to determine its feasibility and help with the planning of a larger study addressed at actual hypothesis testing.

NCT ID: NCT05694754 Recruiting - Clinical trials for Major Depressive Disorder

Transcranial Magnetic Stimulation Theta Burst (TMS), Depression and Smoking.

Start date: October 1, 2021
Phase: N/A
Study type: Interventional

This study evaluates de efficacy of Theta Burst Transcranial Magnetic Stimulation (TMS) applied on the left dorsolateral prefrontal cortex in patients with Major Depressive disorder and tobacco consumption.

NCT ID: NCT05685758 Recruiting - Depression Clinical Trials

A Treatment for Depression Via a Gamified Mobile Phone Application Based on a New Cognitive Model

FTP
Start date: November 3, 2022
Phase: N/A
Study type: Interventional

The study is a randomized controlled treatment study comparing changes in depressive symptoms over 8 weeks between individuals with Major Depressive Disorder (MDD) who have access to an FTP-based mobile phone application and a control group not engaging with the app. FTP, the process of Facilitating Thought Progression, trains the brain's cognitive thought process to expand, accelerate, and be more creative, to alleviate depressive symptoms.

NCT ID: NCT05681767 Recruiting - Depression Clinical Trials

Motivational Multicomponent Lifestyle Interventions as a Supportive Treatment for Depression in Primary Health Care

DEPKuopio
Start date: November 21, 2022
Phase: N/A
Study type: Interventional

The investigators aim to examine whether a motivational multicomponent lifestyle intervention as a supportive treatment for depression has a beneficial effect on recovery from depression in a primary health care setting.

NCT ID: NCT05681130 Recruiting - Pregnancy Clinical Trials

Effect of Depression, Anxiety and Stress Scores on Embryo Transfer Success

Start date: March 1, 2022
Phase:
Study type: Observational [Patient Registry]

Psychological status of couples attending to IVF programmes is important due to possible effect on final result. Observers aim to invertigate the depression, anxiety and stress scores of couples before and after the procedure.

NCT ID: NCT05671588 Recruiting - Multiple Sclerosis Clinical Trials

Cardiovascular Fitness of Patients With Multiple Sclerosis, Effect of Exercise on Fatigue and Depression

Start date: May 1, 2022
Phase: N/A
Study type: Interventional

This study is focused on patients with multiple sclerosis (MS), their cardiovascular fitness, and the effect of combined controlled training on the perception of fatigue, the development of depression, and quality of life in the first year after diagnosis.

NCT ID: NCT05662254 Recruiting - Depression Clinical Trials

PERsonalized Mood Augmentation Trial for Depressed Mood

PERMA
Start date: June 1, 2022
Phase: N/A
Study type: Interventional

The goal of this open-label single-arm study is to test personalized behavioral intervention for depressed mood.

NCT ID: NCT05657691 Recruiting - Clinical trials for Major Depressive Disorder

Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD)

Start date: November 28, 2022
Phase: Phase 2
Study type: Interventional

Xanamem is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD). This XanaCIDD Phase II study in MDD is to investigate the safety and efficacy of Xanamemâ„¢ in treating patients with cognitive and depressive symptoms. Trial participants will be randomized to either receive 10mg of Xanamemâ„¢ once daily or a Placebo at a 1:1 ratio in a double-blinded fashion.

NCT ID: NCT05655754 Recruiting - Depression Clinical Trials

Comparison of Esketamine/Propofol and Methohexital Anesthesia for ECT

Ketofol
Start date: November 1, 2022
Phase: Phase 4
Study type: Interventional

The current anesthetic drug used as standard for ECT procedure at the Department of Psychiatry and Psychotherapy, Medical University of Vienna, is the barbiturate methohexital (Brevital®). As far as we know, methohexital is the most common anesthetic in the procedure of ECT. Only few heterogeneous randomized controlled trials to directly compare the use of (sole) ketamine and methohexital in ECT with relatively small sample sizes have been conducted so far, showing inconclusive findings: a retrospective comparison of methohexital and switch to ketamine anesthesia in 36 patients showed that ketamine prolonged seizure duration and accelerated posttreatment orientation. Others compared both drugs in terms of recovery and reorientation time showing that reorientation time was faster in the methohexital group (total N=9). Another study showed no difference in any outcome measure (depressive symptom improvement, cognition, adverse events) between both groups (total N=16, N=9 per group). Finally, a comparative investigation (total N=37, N=20 vs. N=17) detected no differences between both anesthetics but a higher systolic blood pressure posttreatment and longer motor seizure duration in the ketamine group. A favorable profile of ketamine in regards to seizure quality has been reported, however in terms of outcome measures methohexital and ketamine were similar (total N=50, N=23 vs. N=27). The present study is designed as a prospective randomized non-inferiority trial comparing esketamine plus propofol (ratio 1:1, for better readability from now on referred to as "ketofol") to methohexital, the latter being the current standard anesthetic applied for ECT procedure at our department. Patients eligible for ECT will be randomly assigned to receive anesthesia with either ketofol or methohexital for the whole course of the individual ECT series. Group differences will be investigated both in regards to outcomes related to anesthesia, treatment-outcome and seizure quality. Further, changes in cardiac enzyme levels before and after ECT-treatment and during the entire ECT series will be evaluated and possible group differences will be explored. As stated above the sole/adjunct administration of ketamine as anesthetic agent for ECT has been associated with better seizure quality, similar antidepressant outcomes and anesthesia-associated events, while there is some evidence suggesting that the use of ketamine might present some advantages to other anesthetics in terms of cognitive side-effects accompanying ECT. Therefore, the aim of the present study will be to establish ketofol as a new standard for anesthesia at our Department.